Paul K. Audhya Sells 8,077 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 8,077 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $74,793.02. Following the transaction, the insider now directly owns 94,199 shares of the company’s stock, valued at $872,282.74. The trade was a 7.90 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ:KALV opened at $9.28 on Friday. The business’s 50-day moving average is $11.04 and its 200-day moving average is $11.99. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.39 and a 1 year high of $16.88. The company has a market capitalization of $400.82 million, a price-to-earnings ratio of -2.63 and a beta of 0.92.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.04. Analysts anticipate that KalVista Pharmaceuticals, Inc. will post -2.7 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on KALV shares. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Monday, October 7th. Needham & Company LLC reissued a “buy” rating and set a $32.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of KALV. nVerses Capital LLC bought a new stake in KalVista Pharmaceuticals in the second quarter valued at $25,000. EntryPoint Capital LLC acquired a new stake in shares of KalVista Pharmaceuticals in the 1st quarter valued at about $92,000. China Universal Asset Management Co. Ltd. grew its stake in shares of KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after buying an additional 3,328 shares during the period. Intech Investment Management LLC bought a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at about $126,000. Finally, SG Americas Securities LLC acquired a new position in KalVista Pharmaceuticals during the 3rd quarter worth approximately $153,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).